Seelos Therapeutics, Inc. is a clinical-stage bio-pharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and in rare diseases. The Company’s portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. Seelos’ common stock is traded on The Nasdaq Capital Market under the symbol "SEEL".
Company Details
- Employees
- 7
- Founded
- -
- Address
- 300 Park Avenue,
- in****@****stx.com
- Industry
- Biotechnology
- Website
- seelostherapeutics.com
- Keywords
- Rare Diseases, Parkinson's Disease, Sanfilippo Syndrome, Suicidality, Depression, PTSD, MDD, CNS Disorders, Pharmaceutical, ALS.
- HQ
- New York, New York
Seelos Therapeutics, Inc. Questions
Seelos Therapeutics, Inc.'s website is seelostherapeutics.com
Seelos Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/seelos
Seelos Therapeutics, Inc. has
7 employees.
View email and phone details for 7
employees at Seelos Therapeutics, Inc..
Seelos Therapeutics, Inc.'s industry is
Biotechnology
Seelos Therapeutics, Inc.'s top competitors are
Gh Research Plc,
Mydecine Innovations Group,
Delix Therapeutics,
Mindmed,
Numinus,
Atai Life Sciences,
Compass Pathways,
Cybin Inc,
Gilgamesh Pharmaceuticals,
Transcend Therapeutics.
Seelos Therapeutics, Inc.'s support email address is info@seelostx.com
Seelos Therapeutics, Inc.'s categories are Biotechnology
Seelos Therapeutics, Inc.'s founding year is 2016
